Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Clinical trial NCT00877006 · COMPLETED
Trial details
- NCT number
- NCT00877006
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-04-30
- Primary completion
- 2012-03-31
- Enrollment
- 447
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.